JP2005506367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506367A5 JP2005506367A5 JP2003537620A JP2003537620A JP2005506367A5 JP 2005506367 A5 JP2005506367 A5 JP 2005506367A5 JP 2003537620 A JP2003537620 A JP 2003537620A JP 2003537620 A JP2003537620 A JP 2003537620A JP 2005506367 A5 JP2005506367 A5 JP 2005506367A5
- Authority
- JP
- Japan
- Prior art keywords
- active substance
- pain
- weight
- release
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013543 active substance Substances 0.000 description 19
- 208000002193 Pain Diseases 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000036407 pain Effects 0.000 description 9
- KWTWDQCKEHXFFR-UHFFFAOYSA-N 3-[1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)CC(C)C(CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-UHFFFAOYSA-N 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10152469.2 | 2001-10-24 | ||
| DE10152469A DE10152469A1 (de) | 2001-10-24 | 2001-10-24 | 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung |
| DE10248309.4 | 2002-10-16 | ||
| DE2002148309 DE10248309A1 (de) | 2002-10-16 | 2002-10-16 | 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung |
| PCT/EP2002/011809 WO2003035053A1 (de) | 2001-10-24 | 2002-10-22 | 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010176084A Division JP2010280697A (ja) | 2001-10-24 | 2010-08-05 | 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005506367A JP2005506367A (ja) | 2005-03-03 |
| JP2005506367A5 true JP2005506367A5 (OSRAM) | 2010-10-07 |
| JP4758064B2 JP4758064B2 (ja) | 2011-08-24 |
Family
ID=26010444
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003537620A Expired - Lifetime JP4758064B2 (ja) | 2001-10-24 | 2002-10-22 | 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬 |
| JP2010176084A Pending JP2010280697A (ja) | 2001-10-24 | 2010-08-05 | 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010176084A Pending JP2010280697A (ja) | 2001-10-24 | 2010-08-05 | 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬 |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US20050058706A1 (OSRAM) |
| EP (1) | EP1439829B1 (OSRAM) |
| JP (2) | JP4758064B2 (OSRAM) |
| KR (1) | KR100958045B1 (OSRAM) |
| CN (1) | CN100402021C (OSRAM) |
| AR (1) | AR036943A1 (OSRAM) |
| AT (1) | ATE303802T1 (OSRAM) |
| AU (1) | AU2002349001C1 (OSRAM) |
| BR (1) | BRPI0213653B8 (OSRAM) |
| CA (1) | CA2464578C (OSRAM) |
| CO (1) | CO5570662A2 (OSRAM) |
| CY (1) | CY2012022I1 (OSRAM) |
| DE (1) | DE50204198D1 (OSRAM) |
| DK (1) | DK1439829T3 (OSRAM) |
| EC (1) | ECSP045102A (OSRAM) |
| ES (1) | ES2248622T3 (OSRAM) |
| HU (1) | HU230161B1 (OSRAM) |
| IL (2) | IL161587A0 (OSRAM) |
| MX (1) | MXPA04003742A (OSRAM) |
| MY (1) | MY127797A (OSRAM) |
| NO (2) | NO331896B1 (OSRAM) |
| NZ (1) | NZ532999A (OSRAM) |
| PE (1) | PE20030527A1 (OSRAM) |
| PL (1) | PL216535B1 (OSRAM) |
| PT (1) | PT1439829E (OSRAM) |
| SI (1) | SI1439829T1 (OSRAM) |
| WO (2) | WO2003035053A1 (OSRAM) |
| ZA (1) | ZA200403928B (OSRAM) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| EP1562567B1 (de) | 2002-11-22 | 2017-06-14 | Grünenthal GmbH | Kombination ausgewählter analgetika mit cox ii-inhibitoren |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102004020220A1 (de) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| DE10361596A1 (de) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| ES2289542T3 (es) * | 2003-08-06 | 2008-02-01 | Grunenthal Gmbh | Forma farmaceutica protegida contra un posible abuso. |
| DE102005005446A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE602004007905T2 (de) | 2004-06-28 | 2008-05-08 | Grünenthal GmbH | Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid |
| JP5700904B2 (ja) * | 2004-07-01 | 2015-04-15 | グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | （１ｒ，２ｒ）−３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノールを含有する乱用防止経口投与形態物 |
| DE102004032103A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| EP2012764B1 (en) * | 2006-04-28 | 2011-01-12 | Grünenthal GmbH | Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol |
| PT2012763E (pt) * | 2006-04-28 | 2011-04-29 | Gruenenthal Gmbh | Combinação farmacêutica que compreende 3-(3-dimetilamino-1-etil-2-metil-propil)fenol e um aine |
| CN101091725A (zh) * | 2006-06-23 | 2007-12-26 | 天津天士力制药股份有限公司 | 一种中药颗粒及其制备方法 |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| DE102007011485A1 (de) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| EP1985292A1 (en) * | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
| DE102007019417A1 (de) | 2007-04-23 | 2008-11-13 | Grünenthal GmbH | Tapentadol zur Schmerzbehandlung bei Arthrose |
| KR101607112B1 (ko) * | 2007-11-23 | 2016-03-29 | 그뤼넨탈 게엠베하 | 타펜타돌 조성물 |
| PT2240431T (pt) * | 2007-12-07 | 2017-05-03 | Gruenenthal Gmbh | Modificações cristalinas de (1r,2r)-3-(3-dimetilamino-1- etil-2-metil-propil)fenol |
| US8383152B2 (en) | 2008-01-25 | 2013-02-26 | Gruenenthal Gmbh | Pharmaceutical dosage form |
| TWI524904B (zh) | 2008-05-09 | 2016-03-11 | 歌林達股份有限公司 | 製備醫藥用固體劑型，尤指錠劑之方法，及製備固體劑型，尤指錠劑之前驅物之方法 |
| US20100190752A1 (en) | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
| ES2758831T3 (es) | 2008-10-30 | 2020-05-06 | Gruenenthal Gmbh | Nuevas y potentes formas de dosificación de tapentadol |
| NZ596668A (en) | 2009-07-22 | 2013-09-27 | Gruenenthal Chemie | Oxidation-stabilized tamper-resistant dosage form |
| JP5667183B2 (ja) | 2009-07-22 | 2015-02-12 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 加熱溶融押出成型した制御放出性投与剤型 |
| EP2531176B1 (en) * | 2010-02-03 | 2016-09-07 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of an extruder |
| JP5905872B2 (ja) * | 2010-04-07 | 2016-04-20 | ルピン・リミテッド | タペンタドールの制御放出医薬組成物 |
| US20130116333A1 (en) * | 2010-05-05 | 2013-05-09 | Ratiopharm Gmbh | Solid tapentadol in non-crystalline form |
| US8846765B2 (en) | 2010-06-15 | 2014-09-30 | Gruenenthal Gmbh | Pharmaceutical combination |
| PT2588093T (pt) | 2010-06-30 | 2016-09-21 | Gruenenthal Gmbh | Tapentadol para utilização no tratamento de síndrome do intestino irritável |
| MX341072B (es) | 2010-07-23 | 2016-08-05 | Grünenthal Gmbh * | Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol. |
| MX2013002293A (es) | 2010-09-02 | 2013-05-09 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico. |
| ES2486791T3 (es) | 2010-09-02 | 2014-08-19 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación que comprende una sal inorgánica |
| DK2680833T3 (en) | 2011-03-04 | 2016-05-23 | Gruenenthal Gmbh | PARENTERAL SUBMISSION OF TAPENTADOL |
| CN103501773A (zh) | 2011-03-04 | 2014-01-08 | 格吕伦塔尔有限公司 | 用于口服给予的他喷他多含水药物制剂 |
| LT2694049T (lt) | 2011-04-05 | 2018-12-27 | GrĆ¼nenthal GmbH | Tapentadolis, skirtas skausmo perėjimo į lėtinį prevencijai |
| JP6040219B2 (ja) | 2011-04-05 | 2016-12-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 三叉神経因性痛に伴う疼痛の治療用タペンタドール |
| SI2701693T1 (sl) | 2011-04-29 | 2017-11-30 | Gruenenthal Gmbh | Tapentadol za preprečevanje in zdravljenje depresije in anksioznosti |
| NO2680834T3 (OSRAM) | 2011-05-03 | 2018-03-17 | ||
| WO2013017233A1 (en) | 2011-07-29 | 2013-02-07 | Grünenthal GmbH | Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol |
| EA201400172A1 (ru) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства |
| PE20141650A1 (es) | 2011-07-29 | 2014-11-22 | Gruenenthal Chemie | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco |
| EP2606879A1 (en) | 2011-12-21 | 2013-06-26 | Hexal AG | Multiple unit pellet tablet formulation comprising an opioid |
| WO2013127831A1 (en) | 2012-02-28 | 2013-09-06 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| ES2692944T3 (es) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| BR112015026549A2 (pt) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | forma de dosagem à prova de violação contendo uma ou mais partículas |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| EP2808319A1 (en) | 2013-05-31 | 2014-12-03 | Arevipharma GmbH | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex |
| AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| EP2845625A1 (en) | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
| WO2015071248A1 (en) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Abuse-proofed extended release pharmaceutical composition comprising tapentadol |
| AU2014356581C1 (en) | 2013-11-26 | 2020-05-28 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| EP2942054A1 (en) * | 2014-05-09 | 2015-11-11 | G.L. Pharma GmbH | Slow-release pharmaceutical formulation |
| MX2016014738A (es) | 2014-05-12 | 2017-03-06 | Gruenenthal Gmbh | Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol. |
| CN106456550A (zh) | 2014-05-26 | 2017-02-22 | 格吕伦塔尔有限公司 | 避免乙醇剂量倾泻的多颗粒 |
| ES2710299T3 (es) | 2015-03-27 | 2019-04-24 | Gruenenthal Gmbh | Formulación estable para la administración parenteral de tapentadol |
| BR112017021475A2 (pt) | 2015-04-24 | 2018-07-10 | Gruenenthal Gmbh | forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente |
| CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
| EP3231420A1 (en) | 2016-02-29 | 2017-10-18 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
| ES3027562T3 (en) | 2016-09-23 | 2025-06-16 | Gruenenthal Gmbh | Stable formulation for parenteral administration of tapentadol |
| WO2018153947A1 (en) | 2017-02-23 | 2018-08-30 | Grünenthal GmbH | Tapentadol as local anesthetic |
| US20180369151A1 (en) * | 2017-05-29 | 2018-12-27 | Grünenthal GmbH | Multiparticulate oral dosage form providing prolonged release of tapentadol |
| EP3875080A1 (en) | 2020-03-02 | 2021-09-08 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| AU2020100441B4 (en) * | 2020-03-02 | 2020-06-18 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| BR112022017700A2 (pt) | 2020-03-02 | 2023-01-17 | Gruenenthal Gmbh | Forma de dosagem fornecendo liberação prolongada de sal de ácido fosfórico de tapentadol |
| AU2020100442B4 (en) * | 2020-03-02 | 2020-06-18 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| HUE064779T2 (hu) * | 2020-03-02 | 2024-04-28 | Gruenenthal Gmbh | A tapentadol foszforsav sójának elnyújtott hatóanyag-leadást biztosító adagolási formája |
| ES3010208T3 (en) * | 2020-03-16 | 2025-04-01 | Gruenenthal Gmbh | Scored tablet comprising tapentadol |
| DE202020104285U1 (de) | 2020-07-24 | 2020-12-18 | Grünenthal GmbH | Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure |
| HUE059465T2 (hu) | 2020-11-10 | 2022-11-28 | Gruenenthal Gmbh | A tapentadol L-(+)- borkõsav-só késleltetett felszabadulású adagolási formája |
| DE202020005470U1 (de) | 2020-11-10 | 2022-01-25 | Grünenthal GmbH | Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure |
| WO2022101247A1 (de) | 2020-11-10 | 2022-05-19 | Grünenthal GmbH | Darreichungsformen mit verlängerter freisetzung eines salzes von tapentadol mit l-(+)-weinsäure |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
| DE2117239A1 (de) | 1971-04-08 | 1972-11-16 | König, Wilhelm, 4712 Werne | Verfahren zum Erstellen von Wänden aus Schalungssteinen |
| US4126672A (en) * | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4443428A (en) * | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
| US5641632A (en) | 1983-01-10 | 1997-06-24 | Gen-Probe Incorporated | Method for preparing rRNA for hybridization with a probe |
| US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US4612008A (en) * | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| GB8519310D0 (en) | 1985-07-31 | 1985-09-04 | Zyma Sa | Granular active substances |
| GB8626098D0 (en) * | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
| AU682827B2 (en) * | 1992-09-18 | 1997-10-23 | Astellas Pharma Inc. | Sustained-release hydrogel preparation |
| IL119660A (en) * | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| DE4329794C2 (de) | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
| WO1995014480A1 (en) | 1993-11-17 | 1995-06-01 | Traditional Chinese Medicine Research Laboratory Inc. | Composition for curing lesioned tissue, process for producing the same, and use thereof |
| US5891471A (en) * | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
| US5843480A (en) * | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
| DE4426245A1 (de) * | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
| CN1125572A (zh) * | 1994-12-28 | 1996-07-03 | 顺德市广容制药厂 | 一种罗通定痛释片的制作方法 |
| IL116674A (en) * | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| DE19525137C2 (de) | 1995-07-11 | 2003-02-27 | Gruenenthal Gmbh | 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe |
| DE19609847A1 (de) | 1996-03-13 | 1997-09-18 | Gruenenthal Gmbh | Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe |
| US6096339A (en) | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
| IL123505A (en) * | 1996-07-08 | 2004-12-15 | Penwest Pharmaceuticals Compan | Sustained release matrix for high-dose insoluble drugs |
| DE19630035A1 (de) | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
| EP0998271B3 (en) * | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
| US6106862A (en) * | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
| DE19901683B4 (de) | 1999-01-18 | 2005-07-21 | Grünenthal GmbH | Analgetikum mit kontrollierter Wirkstofffreisetzung |
| WO2001032148A1 (en) * | 1999-10-29 | 2001-05-10 | Euro-Celtique, S.A. | Controlled release hydrocodone formulations |
| DE10109763A1 (de) | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
| DE10248309A1 (de) | 2002-10-16 | 2004-04-29 | Grünenthal GmbH | 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung |
-
2002
- 2002-10-18 PE PE2002001030A patent/PE20030527A1/es active IP Right Grant
- 2002-10-22 DK DK02781278T patent/DK1439829T3/da active
- 2002-10-22 EP EP02781278A patent/EP1439829B1/de not_active Expired - Lifetime
- 2002-10-22 ES ES02781278T patent/ES2248622T3/es not_active Expired - Lifetime
- 2002-10-22 MX MXPA04003742A patent/MXPA04003742A/es active IP Right Grant
- 2002-10-22 KR KR1020047006113A patent/KR100958045B1/ko not_active Expired - Lifetime
- 2002-10-22 WO PCT/EP2002/011809 patent/WO2003035053A1/de not_active Ceased
- 2002-10-22 HU HU0402104A patent/HU230161B1/hu unknown
- 2002-10-22 PT PT02781278T patent/PT1439829E/pt unknown
- 2002-10-22 SI SI200230224T patent/SI1439829T1/sl unknown
- 2002-10-22 JP JP2003537620A patent/JP4758064B2/ja not_active Expired - Lifetime
- 2002-10-22 WO PCT/EP2002/011806 patent/WO2003035054A1/de not_active Ceased
- 2002-10-22 AT AT02781278T patent/ATE303802T1/de active
- 2002-10-22 AU AU2002349001A patent/AU2002349001C1/en active Active
- 2002-10-22 BR BRPI0213653A patent/BRPI0213653B8/pt active IP Right Grant
- 2002-10-22 CA CA2464578A patent/CA2464578C/en not_active Expired - Lifetime
- 2002-10-22 DE DE50204198T patent/DE50204198D1/de not_active Expired - Lifetime
- 2002-10-22 NZ NZ532999A patent/NZ532999A/en not_active IP Right Cessation
- 2002-10-22 CN CNB028259769A patent/CN100402021C/zh not_active Expired - Lifetime
- 2002-10-22 PL PL369756A patent/PL216535B1/pl unknown
- 2002-10-22 IL IL16158702A patent/IL161587A0/xx unknown
- 2002-10-23 AR ARP020104010A patent/AR036943A1/es not_active Application Discontinuation
- 2002-10-24 MY MYPI20023979A patent/MY127797A/en unknown
-
2004
- 2004-04-22 IL IL161587A patent/IL161587A/en active IP Right Grant
- 2004-04-22 CO CO04037005A patent/CO5570662A2/es not_active Application Discontinuation
- 2004-04-26 US US10/831,368 patent/US20050058706A1/en not_active Abandoned
- 2004-05-11 NO NO20041924A patent/NO331896B1/no not_active IP Right Cessation
- 2004-05-12 EC EC2004005102A patent/ECSP045102A/es unknown
- 2004-05-20 ZA ZA2004/03928A patent/ZA200403928B/en unknown
-
2010
- 2010-08-05 JP JP2010176084A patent/JP2010280697A/ja active Pending
-
2011
- 2011-09-23 US US13/242,800 patent/US20120034304A1/en not_active Abandoned
-
2012
- 2012-05-08 NO NO2012007C patent/NO2012007I2/no unknown
- 2012-08-13 CY CY2012022C patent/CY2012022I1/el unknown
-
2013
- 2013-04-23 US US13/868,635 patent/US20130237608A1/en not_active Abandoned
-
2016
- 2016-02-08 US US15/018,529 patent/US20160151309A1/en not_active Abandoned
- 2016-12-13 US US15/377,628 patent/US20170087103A1/en not_active Abandoned
-
2018
- 2018-04-02 US US15/943,175 patent/US20180221308A1/en not_active Abandoned
-
2019
- 2019-10-14 US US16/600,974 patent/US11007156B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506367A5 (OSRAM) | ||
| JP6657454B2 (ja) | ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス | |
| KR101720546B1 (ko) | 구강 삽입용 투여 제형 | |
| JP2010501628A (ja) | 薬物置換療法のためのブプレノルフィンウェハー | |
| JP2019517542A5 (OSRAM) | ||
| JP2005527535A5 (OSRAM) | ||
| EP1085860A1 (en) | Formulations for the treatment of gastro-oesophageal reflux | |
| JP7126260B2 (ja) | 治療処置用の口腔粘膜ナノファイバ担体 | |
| FI87528B (fi) | Foerfarande foer framstaellning av en oral dosenhet av kaliumklorid | |
| EP1594499A1 (en) | Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer | |
| CA2486859A1 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
| PL194702B1 (pl) | Powlekana kompozycja farmaceutyczna w stałej postaci dawkowania i lek zawierający tę kompozycję | |
| RU2528897C2 (ru) | Рецептура для перорального трансмукозального применения гиполипидемических лекарственных средств | |
| JP2005500298A5 (OSRAM) | ||
| JP2006528604A5 (OSRAM) | ||
| EP2464234A1 (en) | Methods for iontophoretically treating nausea and migraine | |
| JP5680412B2 (ja) | レオヌリンの使用およびその組成物 | |
| EP4076381B1 (en) | Transmucosal therapeutic system containing agomelatine | |
| JP2011520868A (ja) | 胃酸分泌を阻害するための組成物および方法 | |
| JP5134973B2 (ja) | 医薬の組み合わせでの処置方法およびこれに適する医薬の組み合わせ | |
| CZ20021315A3 (cs) | Jednotka dávkování | |
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| HU221675B1 (hu) | Hatóanyaghordozó hatóanyagok szabályzott felszabadítására a gyomor-bélcsatornában, késleltetett gyomorkapu-passzázs útján | |
| JP7565912B2 (ja) | 透析移行又は腎死の抑制のための薬剤 | |
| WO2021009197A1 (en) | Dose dumping resistant pharmaceutical compositions comrising verinurad |